MannKind vs Xeris Biopharma
MNKD and XERS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MNKD and XERS compare
Xeris Biopharma is the larger company, worth 2.3 times as much as MannKind ($3.1B against $1.3B).
Xeris Biopharma grew revenue faster over the last twelve months (36.3% versus 30.5% for MannKind).
Xeris Biopharma keeps more of each dollar of sales as profit, with a net margin of −5.1% compared with −11.1% at MannKind.
Xeris Biopharma scores higher on the StockData Score (10 against 6 for MannKind), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MNKD | XERS |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $3.1B |
| Share price | $4.07 | $16.80 |
| Change, 1 year | −19.6% | 134% |
| Change, 5 years | −12.1% | 674% |
| Beta (5Y) | 1.98 | 0.27 |
| Employees | 241 | 435 |
| StockData Score | ||
| Total score | 6 | 10 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 | 4 (better) |
| Performance score | 2 | 3 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.3× (better) | 9.1× |
| EV/EBITDA | 39.8× (better) | 84.2× |
| FCF yield | −1.4% | – |
| Fair value | $1.79 | – |
| Margin of safety | −127% | – |
| Growth | ||
| Revenue growth (TTM) | 30.5% | 36.3% (better) |
| Revenue growth, 5Y average | 39.9% | 70.2% (better) |
| Net income growth (TTM) | −233% | – |
| EPS growth (TTM) | −218% | – |
| Profitability | ||
| Gross margin | 89.8% (better) | 86.6% |
| Operating margin | 2.3% | 10.9% (better) |
| Net margin | −11.1% | −5.1% (better) |
| FCF margin | −4.6% | – |
| Return on invested capital | – | 22.1% |
| Financial health | ||
| Net debt / EBITDA | – | 3.45 |
| Interest coverage | 0.3× | 1.3× (better) |
| Current ratio | 1.72 (better) | 1.45 |
| Altman Z-score | −4.45 | 3.33 (better) |
| Piotroski F-score | 5 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 56.7% | 59.4% |
| Held by insiders | 2.5% | 5.2% |
| Insider net buying, 12 months | −$2.9M (better) | −$5.8M |
| Short interest, % of float | 8.4% | 5.2% |
Go deeper
- MNKD stock overview
- MNKD income statement
- MNKD valuation and score
- XERS stock overview
- XERS income statement
- XERS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.